Oncology

Latest News

US map with stethoscope | Image credit: Andreas Prott – stock.adobe.com

5.5% of US Population Are Cancer Survivors, and the Number Is Growing

By Hayden E. Klein

May 30th 2025

The most prevalent types are prostate cancer among men and breast cancer among women.

ASCO President Robin Zon, MD | Image credit: ASCO

March Toward More Tailored Treatments Continues at ASCO 2025

By Mary Caffrey

May 28th 2025

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 7th 2016

Pembrolizumab's Breakthrough Toughens the Playing Field in NSCLC

Surabhi Dangi-Garimella, PhD

The FDA has accepted for priority review the supplemental Biologics License Application for Merck's pembrolizumab (Keytruda).

September 6th 2016

Whole-Brain Radiotherapy Unnecessary for Brain Metastases in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

Patients with non-small cell lung cancer whose disease has metastasized to the brain can do without whole-brain radiotherapy, according to a new study published in the journal Lancet.

September 3rd 2016

This Week in Managed Care: September 3, 2016

This week in managed care, the top stories included proposals from CMS to shore up the Affordable Care Act's marketplaces, research that highlighted the link between duration of obesity and cancer risk for women, and the results of an FDA diabetes workshop.

September 2nd 2016

Information Disparity a Major Concern of Breast Cancer Survivors

Surabhi Dangi-Garimella, PhD

Researchers at the Sidney Kimmel Cancer Center collated concerns of African American breast cancer survivors to find that medical mistrust was a commonly raised issue.

September 1st 2016

Study Highlights Inconsistent Cancer Screening Guidelines Among High-Risk Transplant Patients

Surabhi Dangi-Garimella, PhD

Results of a new study published in the American Journal of Transplantation has found that international guidelines lack standardization on screening recommendations for solid organ transplant recipients.

September 1st 2016

Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab

Surabhi Dangi-Garimella, PhD

Roche has announced that phase 3 results from the OAK study evaluating atezolizumab (Tecentriq) indicate improved overall survival compared with docetaxel in patients with locally advanced or metastatic non—small cell lung cancer.

August 31st 2016

COA-Commissioned Report Blames PBMs for Restricting Physician Dispensing

Surabhi Dangi-Garimella, PhD

A new report by the law firm Frier Levitt, commissioned by the Community Oncology Alliance, has found that restrictive tactics by pharmacy benefit managers, particularly in the specialty pharmacy arena, could restrict patient access to much needed medications.

August 31st 2016

Evidence-Based Oncology Looks at How the Cost of Cancer Care Affects Treatment

At what point does the cost of cancer therapy affect the results? The current issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, takes on one of today’s biggest treatment challenges: the eye-popping prices of today’s new therapies can erect barriers to care before it begins.

August 30th 2016

Translating a Radiologist's Visual Expertise Into Improving CAD

Surabhi Dangi-Garimella, PhD

Scientists at Brigham and Women’s Hospital are evaluating the depth of a trained radiologist’s eye to detect abnormalities on a mammogram, in an attempt to improve screening and earlier detection of disease.

August 30th 2016

Cancer Risk Increases the Longer a Woman Is Overweight or Obese

Jackie Syrop

A study found that the longer a woman is overweight or obese, the higher the risk of developing several forms of cancer, plus the degree of being overweight plays a role in the risk of developing cancer.

August 29th 2016

PIONEER Trial: Hope for Patients With Unresectable Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

Researchers at Cancer Research UK have developed a strategy to make pancreatic cancer more responsive to chemotherapy and radiation.

August 29th 2016

Infographic: How Young Adult Cancer Survivors Are Hit Hard by Treatment Costs

Laura Joszt, MA

In the August issue of Evidence-Based Oncology, The Samfund's Samantha Watson, MBA, and Michelle Landwehr, MPH, outline how young adult cancer survivors are disproportionately affected by treatment costs. This infographic breaks down the vicious cycle these patients get stuck in.

August 29th 2016

A Thaw in the US—Cuba Relation Could Yield a Lung Cancer Vaccine

Surabhi Dangi-Garimella, PhD

A vaccine, under development in Cuba for more than 2 decades, has shown potential to improve survival in patients with advanced non-small cell lung cancer.

August 26th 2016

Report in NEJM Links 8 More Cancers With Obesity

Mary Caffrey

Researchers found a dose-response relationship for several cancers involved in eating, meaning the higher the weight, the greater risk of cancer.

August 26th 2016

5 Ongoing Initiatives at the FDA

Surabhi Dangi-Garimella, PhD

The FDA has several projects under its wings that can improve the regulatory aspect of drug development and healthcare overall.

August 25th 2016

Does Precision Medicine Aid or Complicate Treatment Decisions in Cancer?

Surabhi Dangi-Garimella, PhD

Based on the results of the MINDACT trial, investigators have concluded that chemotherapy is unnecessary in women with early-stage breast cancer who have a high clinical and low genomic risk of disease recurrence.

August 25th 2016

Dynamic Nature of Breast Cancer Resistance: The HER2 Switch

Surabhi Dangi-Garimella, PhD

Research at Massachusetts General Hospital has provided vital leads that can explain drug resistance observed in breast cancer.

August 24th 2016

Overdiagnosis Blamed for Global Increase in Thyroid Cancer

Surabhi Dangi-Garimella, PhD

Researchers from Italy and France have coauthored an article in the New England Journal of Medicine that blames novel diagnostic technologies, increased access to healthcare services, and increased medical surveillance for the thyroid cancer epidemic around the world

August 23rd 2016

The Final Word Is Out: Menopausal HRT Triples the Risk of Breast Cancer

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Institute of Cancer Research has substantiated that hormone replacement using estrogen and progesterone increases the risk of breast cancer, especially with longer use.

August 22nd 2016

Researchers Propose a Bundled Payment Model for Breast Screening

Surabhi Dangi-Garimella, PhD

A new report by the Harvey L. Neiman Health Policy Institute recommends a bundled payment model for breast cancer screening, with the objective of improved patient care and a more efficient use of healthcare resources.

August 22nd 2016

Adverse Sociodemographic Conditions Reduce Survival in Younger Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Factors such as insurance status and being married are significant determinants of survival compared with race/ethnicity, in patients with multiple myeloma who are less than 65 years of age.

August 20th 2016

This Week in Managed Care: August 20, 2016

This week, the top stories in managed care included Aetna's announcement that it was pulling back its participation on the Affordable Care Act exchanges, the annual meeting of the American Association of Diabetes Educators outlined how existing sites can help roll out the Diabetes Prevention Program nationwide, and hospital leaders gave their opinions on CMS' hospital readmission program.

August 19th 2016

The Toll of Cancer Care - Clinical and Financial Toxicity

Joseph Alvarnas, MD

This issue of Evidence-Based Oncology is dedicated to understanding the implications, scope, and opportunities within the realm of cost sharing in oncology.

August 19th 2016

Does the Cost-Sharing Burden Influence Cancer Outcomes?

Surabhi Dangi-Garimella, PhD

Financial burden is a potential nonclinical adverse event in cancer patients. As patients, especially those in the lower income ranges and the middle class, struggle to meet their medical bills, the likelihood of them skipping doses or doctor’s visits is quite high.

August 19th 2016

Young Adult Cancer Survivors Disproportionately Affected by Treatment Costs

Samantha Watson, MBA Michelle Landwehr, MPH

Young adult (YA) cancer survivors are hit the hardest in the wallet by their treatment. The average net worth of YAs who have received grants from The Samfund is a staggering —$35,000, while their counterparts in the general population is $68,000

August 19th 2016

Precision Oncology: Why Payers Should Initiate CGP Coverage Now!

Jerry Conway Ingrid Marino, MS, CGC

Precision oncology, or the clinically and financially efficient use of genomically matched treatments and clinical trials, is evolving as a potentially important starting point for cancer care within successful alternative payment models.

August 19th 2016

Proton Therapy Eliminates Unnecessary Radiation Exposure and Is Medically Necessary

Steven J. Frank, MD

When it comes to health coverage, most Americans face an unnerving reality-they have no idea what is covered under their health insurance policy until after they are affected by illness or disease.

August 19th 2016

Patient Access to Reference Pricing Prompts Choice of Lower-Cost Testing Laboratories, Cost Savings

Surabhi Dangi-Garimella, PhD

A study by researchers at the University of California, Berkeley, found that patients who have access to the prices charged by a testing laboratory, as well as reference pricing, choose lower-cost laboratories, a move that results in overall cost savings.

August 19th 2016

California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time

Surabhi Dangi-Garimella, PhD

A collaborative pilot that involves the California Department of Public Health, St. Joseph Health in Orange County, and UCSF Benioff Children’s Hospital in Oakland is studying whether near—real-time reporting of cancer diagnoses by pathologists, using standardized electronic forms, will permit providers to make more informed and timely treatment decisions.

August 19th 2016

Breakthrough for Daratumumab for Use as Second-Line Treatment With Standard of Care in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The monoclonal antibody daratumumab (Darzalex) has been granted Breakthrough designation, the second for this drug, for use in combination with either lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with multiple myeloma who have received at least 1 prior therapy.

...

92 93 94 95 96 97 98 99 100

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions